Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
30 mars 2022 16h05 HE
|
Angion Biomedica Corp.
-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -- Ended the year with nearly $89M in cash and cash equivalents ...
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
28 févr. 2022 16h01 HE
|
FibroGen, Inc.
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular...
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
14 févr. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close....
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
04 févr. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink...
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
04 janv. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C....
FibroGen to Report Third Quarter 2021 Financial Results
26 oct. 2021 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. FibroGen will...
Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis
08 sept. 2021 00h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
07 juil. 2021 07h30 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
FibroGen to Report First Quarter 2021 Financial Results
03 mai 2021 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2021 financial results on Monday, May 10 after the market close. FibroGen will also...
FibroGen to Present at Upcoming Investor Conference
28 avr. 2021 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, April 28, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities...